Compare · DFTX vs NAGE
DFTX vs NAGE
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.51B, about 9.4x NAGE ($268.4M).
- Over the past year, DFTX is up 196.5% and NAGE is down 74.8% - DFTX leads by 271.3 points.
- DFTX has been more active in the news (3 items in the past 4 weeks vs 2 for NAGE).
- DFTX has more recent analyst coverage (4 ratings vs 1 for NAGE).
PerformanceDFTX+196.46%NAGE-74.83%
2025-06-09+0.00%2026-06-08
- Company
- Definium Therapeutics Inc.
- Niagen Bioscience Inc.
- Price
- $23.02-2.29%
- $3.38-1.89%
- Market cap
- $2.51B
- $268.4M
- 1M return
- -0.95%
- -19.24%
- 1Y return
- +196.46%
- -74.83%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 2
- Recent ratings
- 4
- 1
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest NAGE
- Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
- Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
- Niagen Bioscience Announces Participation in Upcoming Investor Conferences
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
- SEC Form DEFA14A filed by Niagen Bioscience Inc.
- SEC Form DEF 14A filed by Niagen Bioscience Inc.
- Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™